

Increases in hepatitis C virus infection related to injection
drug use — 30 years — Kentucky, Tennessee, Virginia, and West Virginia

Morbidity and Mortality Weekly Report
2014; 64(15): 453-8

Citation Report

#	ARTICLE	IF	CITATIONS
1	Toward a more accurate estimate of the prevalence of hepatitis C in the United States. <i>Hepatology</i> , 2015, 62, 1353-1363.	7.3	364
2	Reply to direct-acting antiviral drugs and hepatitis C virus: A therapeutic revolution?. <i>Cancer</i> , 2015, 121, 4269-4270.	4.1	0
3	Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1447-1462.	3.0	1
4	The role of social networks and geography on risky injection behaviors of young persons who inject drugs. <i>Drug and Alcohol Dependence</i> , 2015, 154, 229-235.	3.2	38
5	Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3552-3557.	2.3	13
6	Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014. <i>Public Health Reports</i> , 2016, 131, 65-73.	2.5	29
7	Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection. <i>PLoS ONE</i> , 2016, 11, e0165533.	2.5	14
8	Eighteen-to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. <i>Journal of Viral Hepatitis</i> , 2016, 23, 274-281.	2.0	8
9	Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination. <i>Epidemiology and Infection</i> , 2016, 144, 3376-3386.	2.1	5
10	County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 323-331.	2.1	333
11	Treatment utilization among persons with opioid use disorder in the United States. <i>Drug and Alcohol Dependence</i> , 2016, 169, 117-127.	3.2	278
12	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	8.1	80
13	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. <i>Postgraduate Medical Journal</i> , 2016, 92, 356-363.	1.8	22
14	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. <i>Value in Health</i> , 2016, 19, 326-334.	0.3	30
15	Low HIV testing among persons who inject drugs—National HIV Behavioral Surveillance, 2012. <i>Drug and Alcohol Dependence</i> , 2016, 165, 270-274.	3.2	18
16	Performance of Risk-Based and Birth-Cohort Strategies for Identifying Hepatitis C Virus Infection Among People Entering Prison, Wisconsin, 2014. <i>Public Health Reports</i> , 2016, 131, 544-551.	2.5	14
17	Hepatitis C Treatment and Barriers to Eradication. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e193.	2.5	57
18	Opiate Injection-associated Infective Endocarditis in the Southeastern United States. <i>American Journal of the Medical Sciences</i> , 2016, 352, 603-608.	1.1	74

#	ARTICLE	IF	CITATIONS
19	Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?. Substance Use and Misuse, 2016, 51, 1674-1679.	1.4	13
20	Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infectious Diseases, The, 2016, 16, e196-e201.	9.1	37
21	Social context and perspectives of nonâ€œmedical prescription opioid use among young adults in Rhode Island: A qualitative study. American Journal on Addictions, 2016, 25, 659-665.	1.4	21
22	The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials, 2016, 17, 592.	1.6	36
23	Sharing of Snorting Straws and Hepatitis C Virus Infection in Pregnant Women. Obstetrics and Gynecology, 2016, 128, 234-237.	2.4	24
24	Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. Journal of Infectious Diseases, 2016, 214, 344-352.	4.0	12
25	High-impact hepatitis C virus testing for injection drug users in an urban ED. American Journal of Emergency Medicine, 2016, 34, 1108-1111.	1.6	10
26	Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C Virusâ€œInfected Women. Clinical Infectious Diseases, 2016, 62, 980-985.	5.8	94
27	Detoxification from opiate drugs during pregnancy. American Journal of Obstetrics and Gynecology, 2016, 215, 374.e1-374.e6.	1.3	69
28	Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities. International Journal of Drug Policy, 2016, 31, 25-31.	3.3	50
29	The American College of Preventive Medicine Position Statement on Hepatitis C Virus Infection. American Journal of Preventive Medicine, 2016, 50, 419-426.	3.0	5
30	A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. Journal of Virology, 2016, 90, 3773-3782.	3.4	24
31	Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama. Clinical Infectious Diseases, 2016, 62, 613-616.	5.8	6
32	Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department. Clinical Infectious Diseases, 2016, 62, 1059-1065.	5.8	66
33	Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. Clinical Infectious Diseases, 2016, 62, 1066-1071.	5.8	43
34	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. Journal of Virology, 2016, 90, 152-166.	3.4	17
35	Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine, 2017, 129, 102-110.	2.0	22
36	Using database linkages to monitor the continuum of care for hepatitis C virus among syringe exchange clients: Experience from a pilot intervention. International Journal of Drug Policy, 2017, 42, 22-25.	3.3	9

#	ARTICLE	IF	CITATIONS
37	Retention in buprenorphine treatment is associated with improved HCV care outcomes. Journal of Substance Abuse Treatment, 2017, 75, 38-42.	2.8	32
38	Hepatitis C Antibody Testing in a Commercially Insured Population, 2005–2014. American Journal of Preventive Medicine, 2017, 52, 625-631.	3.0	26
39	Geographic Disparities in Access to Syringe Services Programs Among Young Persons With Hepatitis C Virus Infection in the United States. Clinical Infectious Diseases, 2017, 65, 514-517.	5.8	58
40	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct-Acting Antiviral Era. Current Epidemiology Reports, 2017, 4, 174-185.	2.4	48
41	A Public Health Approach to Hepatitis C in an Urban Setting. American Journal of Public Health, 2017, 107, 922-926.	2.7	14
42	Hepatitis C virus infection in children and adolescents. Hepatology Communications, 2017, 1, 87-98.	4.3	64
43	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addictive Disorders and Their Treatment, 2017, 16, S1-S23.	0.5	29
44	Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug and Alcohol Dependence, 2017, 176, 89-95.	3.2	58
45	Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology, 2017, 66, 1102-1110.	7.3	88
46	Down in the valley: Trajectories of injection initiation among young injectors in California’s Central Valley. International Journal of Drug Policy, 2017, 44, 41-49.	3.3	24
47	Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Digestive Diseases and Sciences, 2017, 62, 1373-1380.	2.3	68
48	The safety and effectiveness of ledipasvir/sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology, 2017, 66, 371-378.	7.3	152
49	Self-reported participation in voluntary nonprescription syringe sales in California’s Central Valley. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 677-685.	1.5	21
50	Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics. Digestive Diseases and Sciences, 2017, 62, 3193-3199.	2.3	0
51	Partner Relationships and Injection Sharing Practices among Rural Appalachian Women. Women's Health Issues, 2017, 27, 652-659.	2.0	18
52	The oncologic burden of hepatitis C virus infection: A clinical perspective. Ca-A Cancer Journal for Clinicians, 2017, 67, 411-431.	329.8	88
53	Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs. Journal of Primary Prevention, 2017, 38, 481-494.	1.6	6
54	Fentanyl in the US heroin supply: A rapidly changing risk environment. International Journal of Drug Policy, 2017, 46, 107-111.	3.3	337

#	ARTICLE	IF	CITATIONS
55	Receipt and timing of HIV drug resistance testing in six U.S. jurisdictions. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1567-1575.	1.2	9
56	Impact of Food Insecurity on Depressive Symptoms Among HIV/HCV Co-infected People. <i>AIDS and Behavior</i> , 2017, 21, 3464-3472.	2.7	6
57	Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014. <i>JAMA Pediatrics</i> , 2017, 171, 747.	6.2	214
58	Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 86-94.	3.3	23
59	The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto Rico. <i>BMC Health Services Research</i> , 2017, 17, 232.	2.2	3
60	Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. <i>Harm Reduction Journal</i> , 2017, 14, 25.	3.2	35
61	State HCV Incidence and Policies Related to HCV Preventive and Treatment Services For Persons Who Inject Drugs – United States, 2015–2016. <i>American Journal of Transplantation</i> , 2017, 17, 1945-1948.	4.7	6
62	Opt-out HIV and Hepatitis C Testing at the Dallas County Jail: Uptake, Prevalence, and Demographic Characteristics of Testers. <i>Public Health Reports</i> , 2017, 132, 617-621.	2.5	33
63	Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. <i>Clinical Infectious Diseases</i> , 2017, 64, 1035-1042.	5.8	42
64	Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers. <i>PLoS ONE</i> , 2017, 12, e0188624.	2.5	3
65	Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. <i>PLoS Pathogens</i> , 2017, 13, e1006235.	4.7	47
66	Neonatal Abstinence Syndrome in East Tennessee: Characteristics and Risk Factors among Mothers and Infants in One Area of Appalachia. <i>Journal of Health Care for the Poor and Underserved</i> , 2017, 28, 1393-1408.	0.8	19
67	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. <i>JCI Insight</i> , 2017, 2, .	5.0	129
68	The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions. <i>Current HIV/AIDS Reports</i> , 2018, 15, 96-112.	3.1	123
69	Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned. <i>Current HIV/AIDS Reports</i> , 2018, 15, 113-119.	3.1	14
70	Tennessee’s In-state Vulnerability Assessment for a “Rapid Dissemination of Human Immunodeficiency Virus or Hepatitis C Virus Infection” Event Utilizing Data About the Opioid Epidemic. <i>Clinical Infectious Diseases</i> , 2018, 66, 1722-1732.	5.8	22
71	Update on the management of hepatitis B and C infections in the neonatal period. <i>Seminars in Perinatology</i> , 2018, 42, 185-190.	2.5	6
72	Hepatitis C Virus Knowledge Among Pregnant Women with Opioid Use Disorder. <i>Maternal and Child Health Journal</i> , 2018, 22, 1208-1216.	1.5	7

#	ARTICLE	IF	CITATIONS
73	Differences in time to injection onset by drug in California: Implications for the emerging heroin epidemic. Drug and Alcohol Dependence, 2018, 185, 253-259.	3.2	16
74	Shining a LIGHT Into Drug Darkness. Journal for Nurse Practitioners, 2018, 14, 463-469.e3.	0.8	1
75	Harnessing the language of overdose prevention to advance evidence-based responses to the opioid crisis. International Journal of Drug Policy, 2018, 55, 77-79.	3.3	27
76	The opioid epidemic and injection drug use: MIPIE and health harms related to the injection of prescription opioids. International Journal of Drug Policy, 2018, 57, 130-132.	3.3	7
77	Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. Epidemiology and Infection, 2018, 146, 508-514.	2.1	4
78	Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. Journal of General Internal Medicine, 2018, 33, 551-557.	2.6	36
79	Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. American Journal of Public Health, 2018, 108, 175-181.	2.7	534
80	Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population. Infection, Genetics and Evolution, 2018, 58, 77-82.	2.3	12
81	Drug Use and Incarceration among Rural Appalachian Women: Findings From a Jail Sample. Substance Use and Misuse, 2018, 53, 931-941.	1.4	33
82	Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. Journal of Infectious Diseases, 2018, 217, 1020-1023.	4.0	6
83	Hepatitis C Virus Screening Among Children Exposed During Pregnancy. Pediatrics, 2018, 141, .	2.1	85
84	Common mental disorders and psychological adjustment among individuals seeking HIV testing: a study protocol to explore implications for mental health care systems. International Journal of Mental Health Systems, 2018, 12, 16.	2.7	8
85	Addressing the growing opioid and heroin abuse epidemic: a call for medical school curricula. Medical Education Online, 2018, 23, 1466574.	2.6	29
86	Feasibility of ecological momentary assessment to study mood and risk behavior among young people who inject drugs. Drug and Alcohol Dependence, 2018, 187, 227-235.	3.2	32
87	Scaling up HCV prevention and treatment interventions in rural United States model projections for tackling an increasing epidemic. Addiction, 2018, 113, 173-182.	3.3	71
88	Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach. Journal of Viral Hepatitis, 2018, 25, 28-36.	2.0	4
89	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology, 2018, 67, 837-846.	7.3	61
90	The rise of the opioid epidemic and hepatitis C – positive organs: A new era in liver transplantation. Hepatology, 2018, 67, 1600-1608.	7.3	62

#	ARTICLE	IF	CITATIONS
91	High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members. <i>Journal of Urban Health</i> , 2018, 95, 71-82.	3.6	22
92	Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 310-316.	2.1	12
93	Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse. <i>Journal of Pediatrics</i> , 2018, 192, 159-164.	1.8	38
94	How to eliminate HCV in people who inject drugs in the USA. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 134-135.	9.1	8
95	Needlestick Injuries Among Emergency Medical Services Providers in Urban and Rural Areas. <i>Journal of Community Health</i> , 2018, 43, 518-523.	3.8	13
96	Prevalence of Hepatitis C Screening, Testing, and Care Experience Among Young Adults Who Use Prescription Opioids Nonmedically. <i>Journal of Adolescent Health</i> , 2018, 62, 114-117.	2.5	2
97	Correlates of Injection Drug Use Among Rural Appalachian Women. <i>Journal of Rural Health</i> , 2018, 34, 31-41.	2.9	28
98	Prevalence of Maternal Hepatitis C Virus Infection in Ohio. <i>Obstetrics and Gynecology</i> , 2018, 132, 708-716.	2.4	15
99	Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia. <i>Journal of Addictive Diseases</i> , 2018, 37, 1-4.	1.3	9
100	HIV and the Liver. , 2018, , 536-555.e7.		1
101	Hepatitis C Within a Single Health System: Progression Along the Cascade to Cure Is Higher for Those With Substance Misuse When Linked to a Clinic With Embedded Support Services. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy202.	0.9	9
102	A large HCV transmission network enabled a fast-growing HIV outbreak in rural Indiana, 2015. <i>EBioMedicine</i> , 2018, 37, 374-381.	6.1	51
103	Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine. <i>Frontiers in Immunology</i> , 2018, 9, 2577.	4.8	1
104	Implementation of a Collaborative HIV and Hepatitis C Screening Program in Appalachian Urgent Care Settings. <i>Western Journal of Emergency Medicine</i> , 2018, 19, 1057-1064.	1.1	13
105	Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 532.	2.9	95
106	Qualitative case study of needle exchange programs in the Central Appalachian region of the United States. <i>PLoS ONE</i> , 2018, 13, e0205466.	2.5	21
107	Prevalence of hepatitis C viral infection among injecting drug users in a Saudi Arabian hospital: A point cross sectional survey. <i>Journal of Public Health in Africa</i> , 2018, 9, 726.	0.4	5
108	HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. <i>PLoS ONE</i> , 2018, 13, e0204795.	2.5	10

#	ARTICLE	IF	CITATIONS
109	Peer-to-peer injection: Demographic, drug use, and injection-related risk factors. International Journal of Drug Policy, 2018, 61, 44-51.	3.3	8
110	Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. AIDS Patient Care and STDs, 2018, 32, 529-537.	2.5	86
111	HIV Prevention in Rural Appalachian Jails: Implications for Re-entry Risk Reduction Among Women Who Use Drugs. AIDS and Behavior, 2018, 22, 4009-4018.	2.7	12
112	Hepatitis C Virus in Women of Childbearing Age, Pregnant Women, and Children. American Journal of Preventive Medicine, 2018, 55, 633-641.	3.0	39
113	Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. Clinical Infectious Diseases, 2018, 67, 1493-1497.	5.8	45
114	Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder. JAMA Pediatrics, 2018, 172, 1029.	6.2	141
115	Trends in non-medical prescription opioids and heroin co-use among adults, 2003â€“2014. Addictive Behaviors, 2018, 86, 17-23.	3.0	21
116	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infectious Disease Clinics of North America, 2018, 32, 371-393.	5.1	27
117	The Road to Hepatitis C Virus Cure. Infectious Disease Clinics of North America, 2018, 32, 481-493.	5.1	3
118	Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: A systematic review. Drug and Alcohol Dependence, 2018, 188, 239-250.	3.2	50
119	Federal Response to the Opioid Crisis. Current HIV/AIDS Reports, 2018, 15, 293-301.	3.1	39
120	Diffusion of medication drop-boxes in North Carolina from 2007 to 2016. Addictive Behaviors, 2018, 86, 44-50.	3.0	10
121	Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. Paediatric and Perinatal Epidemiology, 2018, 32, 401-410.	1.7	12
122	Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013â€“2016. Advances in Therapy, 2018, 35, 1087-1102.	2.9	22
123	HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia. Current HIV/AIDS Reports, 2018, 15, 308-314.	3.1	5
124	Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention. Current HIV/AIDS Reports, 2018, 15, 324-335.	3.1	21
125	Direct-acting antiviral treatment of acute hepatitis C virus infections. Expert Review of Anti-Infective Therapy, 2018, 16, 599-610.	4.4	3
126	Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001â€“2012. Open Forum Infectious Diseases, 2018, 5, ofy144.	0.9	10

#	ARTICLE	IF	CITATIONS
127	Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition. <i>Current HIV/AIDS Reports</i> , 2018, 15, 276-282.	3.1	21
128	Pharmacistsâ€™ role in harm reduction: a survey assessment of Kentucky community pharmacistsâ€™ willingness to participate in syringe/needle exchange. <i>Harm Reduction Journal</i> , 2018, 15, 4.	3.2	23
129	Unique Challenges of Hepatitis C in Infants, Children, and Adolescents. <i>Clinical Therapeutics</i> , 2018, 40, 1299-1307.	2.5	22
130	Hepatitis C virus infection in children: How do we prevent it and how do we treat it?. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 689-694.	4.4	26
131	Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment. <i>Current HIV/AIDS Reports</i> , 2018, 15, 315-323.	3.1	25
132	Hepatitis B Vaccines. , 2018, , 342-374.e17.		13
133	Knowledge of Hepatitis C Risk Factors is Lower in High Incidence Regions. <i>Journal of Community Health</i> , 2019, 44, 12-15.	3.8	6
134	Trends in Adolescent Heroin and Injection Drug Use in Nine Urban Centers in the U.S., 1999â€“2017. <i>Journal of Adolescent Health</i> , 2019, 65, 210-215.	2.5	14
135	Integration of Hepatitis C Treatment in a Primary care Federally Qualified Health Center; Philadelphia, Pennsylvania, 2015-2017. <i>Infectious Diseases: Research and Treatment</i> , 2019, 12, 117863371984138.	1.7	14
136	Costâ€effectiveness of scalingâ€up HCV prevention and treatment in the United States for people who inject drugs. <i>Addiction</i> , 2019, 114, 2267-2278.	3.3	28
137	Factors Correlating to the Development of Hepatitis C Virus Infection among Drug Usersâ€Findings from a Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2345.	2.6	10
138	How Clinicians Caring for Youth Can Address the Opioid-Related Overdose Crisis. <i>Journal of Adolescent Health</i> , 2019, 65, 177-180.	2.5	22
139	The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance. <i>Preventive Medicine</i> , 2019, 128, 105740.	3.4	19
140	Explaining Pharmacy Studentsâ€™ Dispensing Intentions in Substance Abuse-Related Gray Areas Using the Theory of Planned Behavior. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 6767.	2.1	2
141	Hepatitis C virus infection in children and adolescents. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 477-487.	8.1	117
142	I could take the judgment if you could just provide the service: non-prescription syringe purchase experience at Arizona pharmacies, 2018. <i>Harm Reduction Journal</i> , 2019, 16, 57.	3.2	22
143	Social norms associated with nonmedical opioid use in rural communities: a systematic review. <i>Translational Behavioral Medicine</i> , 2019, 9, 1224-1232.	2.4	19
144	Changes in Reported Injection Behaviors Following the Public Health Response to an HIV Outbreak Among People Who Inject Drugs: Indiana, 2016. <i>AIDS and Behavior</i> , 2019, 23, 3257-3266.	2.7	11

#	ARTICLE	IF	CITATIONS
145	Hepatitis C virus modelled as an indirectly transmitted infection highlights the centrality of injection drug equipment in disease dynamics. <i>Journal of the Royal Society Interface</i> , 2019, 16, 20190334.	3.4	9
146	Geographic Trends, Patient Characteristics, and Outcomes of Infective Endocarditis Associated With Drug Abuse in the United States From 2002 to 2016. <i>Journal of the American Heart Association</i> , 2019, 8, e012969.	3.7	103
147	Opioid epidemic and liver disease. <i>JHEP Reports</i> , 2019, 1, 240-255.	4.9	18
148	Distributive Syringe Sharing and Use of Syringe Services Programs (SSPs) Among Persons Who Inject Drugs. <i>AIDS and Behavior</i> , 2019, 23, 3306-3314.	2.7	11
149	Potential disease burden of patients with substance abuse undergoing major abdominal surgery: A propensity score-matched analysis. <i>Surgery</i> , 2019, 166, 1181-1187.	1.9	4
150	Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999–2016. <i>Journal of Infectious Diseases</i> , 2020, 221, 408-418.	4.0	19
151	A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. <i>Health Affairs</i> , 2019, 38, 287-294.	5.2	60
152	Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. <i>Harm Reduction Journal</i> , 2019, 16, 33.	3.2	54
153	Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system. <i>PLoS ONE</i> , 2019, 14, e0216459.	2.5	20
154	Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. <i>Scientific Reports</i> , 2019, 9, 9251.	3.3	42
155	The phylogenetic approach for viral infectious disease evolution and epidemiology: An updating review. <i>Journal of Medical Virology</i> , 2019, 91, 1707-1724.	5.0	16
156	Acute Hepatitis C. , 2019, , 197-217.		0
157	Risk Factors Associated with Linkage to Care among Suburban Hepatitis C-Positive Baby Boomers and Injection Drug Users. <i>Infectious Diseases and Therapy</i> , 2019, 8, 417-428.	4.0	5
158	Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. <i>American Journal of Epidemiology</i> , 2019, 188, 1539-1551.	3.4	29
159	Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-6.	1.9	10
160	Gaps in HCV Knowledge and Risk Behaviors among Young Suburban People Who Inject Drugs. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1958.	2.6	19
161	Acute HCV Treatment: What Should We Do in the DAA Era?. <i>Current Hepatology Reports</i> , 2019, 18, 216-221.	0.9	0
162	Rural risk environments for hepatitis c among young adults in appalachian kentucky. <i>International Journal of Drug Policy</i> , 2019, 72, 47-54.	3.3	29

#	ARTICLE	IF	CITATIONS
163	Testing for Hepatitis C in Pregnancy: the Time Has Come for Routine Rather than Risk-Based. Current Hepatology Reports, 2019, 18, 206-215.	0.9	7
164	Estimated cost of comprehensive syringe service program in the United States. PLoS ONE, 2019, 14, e0216205.	2.5	14
165	Contact tracing for hepatitis C: The case for novel screening strategies as we strive for viral elimination. International Journal of Drug Policy, 2019, 72, 33-39.	3.3	19
166	Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships. Open Forum Infectious Diseases, 2019, 6, ofz125.	0.9	7
167	Barriers to using new needles encountered by rural Appalachian people who inject drugs: implications for needle exchange. Harm Reduction Journal, 2019, 16, 23.	3.2	20
168	Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. Epidemics, 2019, 27, 86-95.	3.0	21
169	Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clinical Transplantation, 2019, 33, e13514.	1.6	56
170	Rising role of prescription drugs as a portal to injection drug use and associated mortality in Baltimore, Maryland. PLoS ONE, 2019, 14, e0213357.	2.5	12
171	Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users. Journal of Psychoactive Drugs, 2019, 51, 311-322.	1.7	8
172	Treatment and monitoring of children with chronic hepatitis C in the Pre-DAAs era: A European survey of 38 paediatric specialists. Journal of Viral Hepatitis, 2019, 26, 961-968.	2.0	15
173	Opioid agonist treatment and the process of injection drug use initiation. Drug and Alcohol Dependence, 2019, 197, 354-360.	3.2	26
174	Increased HIV diagnoses in West Virginia counties highly vulnerable to rapid HIV dissemination through injection drug use: a cautionary tale. Annals of Epidemiology, 2019, 34, 12-17.	1.9	31
175	Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clinical Infectious Diseases, 2019, 69, 514-522.	5.8	20
176	Inconsistent temporal patterns of genetic variation of HCV among high-risk subjects may impact inference of transmission networks. Infection, Genetics and Evolution, 2019, 71, 1-6.	2.3	2
177	Acute Hepatitis C. , 2019, , 45-65.		0
178	Evaluation of the Aptima HCV Quant Dx Assay Using Serum and Dried Blood Spots. Journal of Clinical Microbiology, 2019, 57, .	3.9	5
179	New Face of Hepatitis C. Digestive Diseases and Sciences, 2019, 64, 1782-1788.	2.3	19
180	Management of Hepatitis C. Gastroenterology Nursing, 2019, Publish Ahead of Print, 22-27.	0.4	0

#	ARTICLE	IF	CITATIONS
181	Drug Misuse and Hepatitis C Virus Infection Profiles for Three Generations of Patients Being Monitored for Prescription Drug Adherence. <i>Journal of Addiction Medicine</i> , 2019, 13, 123-130.	2.6	1
182	HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco. <i>PLoS ONE</i> , 2019, 14, e0226166.	2.5	12
183	Mortality, morbidity, and cardiac surgery in Injection Drug Use (IDU)-associated versus non-IDU infective endocarditis: The need to expand substance use disorder treatment and harm reduction services. <i>PLoS ONE</i> , 2019, 14, e0225460.	2.5	40
184	“We don't get much of a voice about anything” perspectives on photovoice among people who inject drugs. <i>Harm Reduction Journal</i> , 2019, 16, 61.	3.2	10
185	Opioid-Related Diagnoses and Concurrent Claims for HIV, HBV, or HCV among Medicare Beneficiaries, United States, 2015. <i>Journal of Clinical Medicine</i> , 2019, 8, 1768.	2.4	3
186	Hepatitis C Virus Antibody Testing Among 13- to 21-Year-Olds in a Large Sample of US Federally Qualified Health Centers. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2245.	7.4	10
187	Hepatitis C Virus Infection in Indigenous Populations in the United States and Canada. <i>Epidemiologic Reviews</i> , 2019, 41, 158-167.	3.5	14
188	Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. <i>Pain Practice</i> , 2019, 19, 443-454.	1.9	9
189	Systemic Issues in the Opioid Epidemic: Supporting the Individual, Family, and Community. <i>International Journal of Mental Health and Addiction</i> , 2019, 17, 1214-1228.	7.4	7
190	Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. <i>Hepatology</i> , 2019, 69, 1020-1031.	7.3	374
191	HIV conspiracy theory beliefs mediates the connection between HIV testing attitudes and HIV prevention self-efficacy. <i>Journal of American College Health</i> , 2019, 67, 661-673.	1.5	6
192	In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. <i>Antiviral Research</i> , 2019, 162, 136-141.	4.1	4
193	Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City. <i>Drug and Alcohol Dependence</i> , 2019, 194, 453-459.	3.2	10
194	Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. <i>Drug and Alcohol Dependence</i> , 2019, 195, 114-120.	3.2	31
195	Increased HCV Screening Yields Discordant Gains in Diagnoses Among Urban and Rural Veteran Populations in Texas: Results of a Statewide Quality Improvement Initiative. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019, 45, 112-122.	0.7	2
196	Clinical Epidemiology of Hepatitis C Virus. , 2019, , 149-170.		1
197	National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 806-821.	1.8	2
198	(Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States. <i>Hepatology</i> , 2019, 69, 1832-1834.	7.3	0

#	ARTICLE	IF	CITATIONS
199	Promising roles for pharmacists in addressing the U.S. opioid crisis. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 910-916.	3.0	76
200	Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia. <i>Journal of Community Health</i> , 2020, 45, 239-244.	3.8	37
201	A Call to Action: HCV Treatment of People Who Inject Drugs in the United States. <i>Clinical Infectious Diseases</i> , 2020, 70, 2366-2368.	5.8	4
202	Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 921-929.	1.2	3
203	Initiating Persons into Injection Drug Use in Rural West Virginia, USA. <i>Substance Use and Misuse</i> , 2020, 55, 337-344.	1.4	6
204	Hepatitis C Virus Screening Among Adolescents Attending a Drug Rehabilitation Center. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 437-441.	1.3	9
205	Correlates of Transactional Sex Among a Rural Population of People Who Inject Drugs. <i>AIDS and Behavior</i> , 2020, 24, 775-781.	2.7	29
206	Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases. <i>Clinical Infectious Diseases</i> , 2020, 70, 968-972.	5.8	45
207	Motivation to Change and Treatment Participation Among Syringe Service Program Utilizers in Rural Kentucky. <i>Journal of Rural Health</i> , 2020, 36, 224-233.	2.9	8
208	Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. <i>International Journal of Drug Policy</i> , 2020, 85, 102602.	3.3	16
209	Peer influence of injection drug use cessation among dyads in rural eastern Kentucky. <i>International Journal of Drug Policy</i> , 2020, 85, 102604.	3.3	7
210	Opioid use disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 3.	30.5	278
211	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. <i>JAMA Psychiatry</i> , 2020, 77, 493.	11.0	83
212	Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 193-199.	1.1	5
213	Evaluating the impact of Georgia's hepatitis C elimination plan: lessons learned for the global initiative. <i>The Lancet Global Health</i> , 2020, 8, e163-e164.	6.3	6
214	Utilizing Electronic Laboratory Reporting Data to Assess the Burden of Hepatitis C in Arizona. <i>Journal of Public Health Management and Practice</i> , 2020, 26, 562-569.	1.4	2
215	Pregnancy Status, Risk Factors, and Opportunities for Referral to Care Among Reproductive-Aged Women With Newly Reported Chronic Hepatitis C Virus Infection in Tennessee. <i>Public Health Reports</i> , 2020, 135, 90-96.	2.5	6
216	Syringe access and health harms: Characterizing "ecolandscapes of antagonism" in California's Central Valley. <i>International Journal of Drug Policy</i> , 2020, 75, 102594.	3.3	13

#	ARTICLE	IF	CITATIONS
217	Management of Hepatitis C in Children and Adolescents. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 785-790.	1.3	2
218	Evaluating Differences in Opioid and Stimulant Use-associated Infectious Disease Hospitalizations in Florida, 2016–2017. Clinical Infectious Diseases, 2021, 73, e1649-e1657.	5.8	23
219	Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region. Journal of Infectious Diseases, 2020, 222, S354-S364.	4.0	12
220	Human Immunodeficiency Virus Testing, Diagnosis, Linkage to Care, and Prevention Services Among Persons Who Inject Drugs, United States, 2012–2017. Journal of Infectious Diseases, 2020, 222, S268-S277.	4.0	3
221	Healthcare Access and Utilization Among Persons Who Inject Drugs in Medicaid Expansion and Nonexpansion States: 22 United States Cities, 2018. Journal of Infectious Diseases, 2020, 222, S420-S428.	4.0	13
222	Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014. Public Health Reports, 2020, 135, 461-471.	2.5	4
223	Contraceptive use in Appalachian women who use drugs and were recruited from rural jails. Social Work in Health Care, 2020, 59, 365-386.	1.6	8
224	Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study. American Journal of Medicine, 2020, 133, e641-e658.	1.5	5
225	Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations. Vaccine, 2020, 38, 8206-8215.	3.8	15
226	The Clinical Microbiology Laboratory and the Opioid Epidemic. Infectious Disease Clinics of North America, 2020, 34, 465-478.	5.1	0
227	Applying the Infectious Diseases Literature to People who Inject Drugs. Infectious Disease Clinics of North America, 2020, 34, 539-558.	5.1	13
228	Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver International, 2020, 40, 2407-2416.	3.9	19
229	Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination. Seminars in Liver Disease, 2020, 40, 213-224.	3.6	13
230	State of the Hepatitis C Virus Care Cascade. Clinical Liver Disease, 2020, 16, 8-11.	2.1	16
231	Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. Lancet Microbe, The, 2020, 1, e200-e208.	7.3	74
232	Screening for Hepatitis C Virus: How Universal Is Universal?. Clinical Therapeutics, 2020, 42, 1434-1441.	2.5	7
233	Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women. Obstetrics and Gynecology, 2020, 135, 778-788.	2.4	16
234	Syringe Service Program Utilization, Barriers, and Preferences for Design in Rural Appalachia: Differences between Men and Women Who Inject Drugs. Substance Use and Misuse, 2020, 55, 2268-2277.	1.4	21

#	ARTICLE	IF	CITATIONS
235	Impact of the Opioid Epidemic. Critical Care Clinics, 2020, 36, 753-769.	2.6	12
236	HaRePo (harm reduction by post): an innovative and effective harm reduction programme for people who use drugs using email, telephone, and post service. Harm Reduction Journal, 2020, 17, 59.	3.2	8
237	A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. Harm Reduction Journal, 2020, 17, 64.	3.2	10
238	Novel Recruitment Methods for Research Among Young Adults in Rural Areas Who Use Opioids: Cookouts, Coupons, and Community-Based Staff. Public Health Reports, 2020, 135, 746-755.	2.5	11
239	Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial. Journal of Infectious Diseases, 2020, 222, S376-S383.	4.0	11
240	Understanding rural risk environments for drug-related harms: Progress, challenges, and steps forward. International Journal of Drug Policy, 2020, 85, 102926.	3.3	12
241	Widespread septic embolization in injection drug use mitro-aortic infective endocarditis as a remote cause of death. International Journal of Legal Medicine, 2020, 134, 1345-1351.	2.2	3
242	Viral hepatitis in patients on hemodialysis. Seminars in Dialysis, 2020, 33, 254-262.	1.3	4
243	Treatment of Hepatitis C: A New Paradigm toward Viral Eradication. Journal of Pediatrics, 2020, 221, 12-22.e1.	1.8	7
244	A Big Step Forward in Hepatitis C Screening. Clinical Liver Disease, 2020, 15, 149-152.	2.1	3
245	Competing forces of withdrawal and disease avoidance in the risk networks of people who inject drugs. PLoS ONE, 2020, 15, e0235124.	2.5	5
246	High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department. PLoS ONE, 2020, 15, e0233927.	2.5	18
247	Animal Models Used in Hepatitis C Virus Research. International Journal of Molecular Sciences, 2020, 21, 3869.	4.1	23
248	Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. International Journal of Drug Policy, 2020, 85, 102701.	3.3	64
249	Individual and network factors associated with HCV treatment uptake among people who inject drugs. International Journal of Drug Policy, 2020, 78, 102714.	3.3	19
250	HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic. Journal of General Internal Medicine, 2020, 35, 1477-1483.	2.6	12
251	Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis. International Journal of Drug Policy, 2020, 78, 102716.	3.3	32
252	The Health Resources and Services Administration's Ryan White HIV/AIDS Program in rural areas of the United States: Geographic distribution, provider characteristics, and clinical outcomes. PLoS ONE, 2020, 15, e0230121.	2.5	7

#	ARTICLE	IF	CITATIONS
253	Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL. Harm Reduction Journal, 2020, 17, 40.	3.2	21
254	Don't Wait: The Benefits of Early Diagnosis in Perinatal Hepatitis C Virus Transmission. Clinical Infectious Diseases, 2021, 73, e3347-e3348.	5.8	1
255	Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy. Clinical Infectious Diseases, 2021, 73, e3340-e3346.	5.8	18
256	Factors Associated With Testing for Hepatitis C Infections Among a Commercially Insured Population of Persons With HIV, United States 2008–2016. Open Forum Infectious Diseases, 2020, 7, ofaa222.	0.9	1
257	Age- and risk factor-based serologic screening for Hepatitis C virus among an Urban, high-risk population. Journal of Viral Hepatitis, 2020, 27, 1369-1387.	2.0	0
258	Centers for Disease Control and Prevention Recommendations for Hepatitis C Testing: The Need to Adopt Universal Screening in an Appalachian Emergency Department. Academic Emergency Medicine, 2020, 27, 844-852.	1.8	3
259	Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections and Injection Drug Use, Tennessee, USA, 2015–2017. Emerging Infectious Diseases, 2020, 26, .	4.3	26
260	Reported Prevalence of Maternal Hepatitis C Virus Infection in the United States. Obstetrics and Gynecology, 2020, 135, 387-395.	2.4	32
261	We Need a New National Strategy for Hepatitis C Virus Screening. Pediatrics, 2020, 145, .	2.1	3
262	Reasons for assisting with injection initiation: Results from a large survey of people who inject drugs in Los Angeles and San Francisco, California. Drug and Alcohol Dependence, 2020, 209, 107885.	3.2	11
263	Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. Journal of Viral Hepatitis, 2020, 27, 663-670.	2.0	18
264	Animal Models of Hepatitis C Virus Infection. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036970.	6.2	16
265	Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky. Drug and Alcohol Dependence, 2020, 208, 107837.	3.2	11
266	Mitigating the Risk of Infectious Diseases Among Rural Drug Users in Western North Carolina: Results of the Southern Appalachia Test, Link, Care (SALT) Health Care Provider Survey. Journal of Rural Health, 2020, 36, 208-216.	2.9	3
267	Barriers and facilitators to retaining a cohort of street-based cisgender female sex workers recruited in Baltimore, Maryland, USA: results from the SAPPHIRE study. BMC Public Health, 2020, 20, 585.	2.9	10
268	Hepatitis C Testing Among Perinatally Exposed Infants. Pediatrics, 2020, 145, .	2.1	35
269	Infective Endocarditis Among Persons Aged 18–64 Years Living with Human Immunodeficiency Virus, Hepatitis C Infection, or Opioid Use Disorder, United States, 2007–2017. Clinical Infectious Diseases, 2021, 72, 1767-1781.	5.8	25
270	Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. International Journal of Drug Policy, 2021, 88, 102707.	3.3	14

#	ARTICLE	IF	CITATIONS
271	Outcomes of femoral artery ligation for treatment of infected femoral pseudoaneurysms due to drug injection. <i>Journal of Vascular Surgery</i> , 2021, 73, 635-640.	1.1	11
272	Social network predictors of recent and sustained injection drug use cessation: findings from a longitudinal cohort study. <i>Addiction</i> , 2021, 116, 856-864.	3.3	5
273	A multivariate spatio-temporal model of the opioid epidemic in Ohio: a factor model approach. <i>Health Services and Outcomes Research Methodology</i> , 2021, 21, 42-53.	1.8	1
274	High Prevalence of Indications for Pre-exposure Prophylaxis Among People Who Inject Drugs in Boston, Massachusetts. <i>American Journal of Preventive Medicine</i> , 2021, 60, 369-378.	3.0	13
275	Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 185-198.	4.5	9
276	A Population-Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection. <i>Hepatology Communications</i> , 2021, 5, 387-399.	4.3	11
277	Willingness to Participate in At-Home HIV Testing Among Young Adults Who Use Opioids in Rural Appalachia. <i>AIDS and Behavior</i> , 2021, 25, 699-708.	2.7	11
278	Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 71-74.	1.3	2
279	Correlates of Transactional Sex and Violent Victimization among Men Who Inject Drugs in Los Angeles and San Francisco, California. <i>Journal of Urban Health</i> , 2021, 98, 70-82.	3.6	12
280	Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e23080.	3.7	15
281	Hepatitis C virus infection and polysubstance use among young adult people who inject drugs in a rural county of New Mexico. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108527.	3.2	10
282	Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108526.	3.2	10
283	Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky. <i>Journal of Rural Health</i> , 2022, 38, 93-99.	2.9	2
284	International Classification of Diseases (ICD) Codes Fail to Accurately Identify Injection Drug Use Associated Endocarditis Cases. <i>Journal of Addiction Medicine</i> , 2022, 16, 27-32.	2.6	3
285	Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs. <i>Journal of Urban Health</i> , 2021, 98, 532-537.	3.6	10
286	Harm Reduction for Adolescents and Young Adults During the COVID-19 Pandemic: A Case Study of Community Care in Reach. <i>Public Health Reports</i> , 2021, 136, 301-308.	2.5	8
287	Outbreak of hepatitis B and hepatitis C virus infections associated with a cardiology clinic, West Virginia, 2012-2014. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1458-1463.	1.8	2
288	Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108589.	3.2	16

#	ARTICLE	IF	CITATIONS
289	Syringe Coverage Among People Who Inject Drugs in West Virginia, USA. <i>AIDS and Behavior</i> , 2021, 25, 3377-3385.	2.7	7
290	Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108626.	3.2	14
291	Living at the Confluence of Stigmas: PrEP Awareness and Feasibility Among People Who Inject Drugs in Two Predominantly Rural States. <i>AIDS and Behavior</i> , 2021, 25, 3085-3096.	2.7	13
292	Disparities in Awareness of Hepatitis C Virus Among US Adults: An Analysis of the 2019 Health Information National Trends Survey. <i>Sexually Transmitted Diseases</i> , 2021, 48, 981-985.	1.7	4
293	The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018. <i>American Journal of Public Health</i> , 2021, 111, 949-955.	2.7	25
294	Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. <i>Adolescent Health, Medicine and Therapeutics</i> , 2021, Volume 12, 45-53.	0.9	3
295	Using the electronic medical record to increase testing for HIV and hepatitis C virus in an Appalachian emergency department. <i>BMC Health Services Research</i> , 2021, 21, 524.	2.2	6
296	Ruralâ€“Urban Residence and Maternal Hepatitis C Infection, U.S.: 2010â€“2018. <i>American Journal of Preventive Medicine</i> , 2021, 60, 820-830.	3.0	8
297	Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications. <i>PLoS ONE</i> , 2021, 16, e0252976.	2.5	5
298	Medication assisted therapy and recovery homes. <i>Journal of Prevention and Intervention in the Community</i> , 2021, , 1-13.	0.7	1
299	Responsible Inclusion of Pregnant Individuals in Eradicating HCV. <i>Hepatology</i> , 2021, 74, 1645-1651.	7.3	17
300	Racial disparities in use of non-emergency outpatient care by Medicaid-eligible adults after release from prison: Wisconsin, 2015â€“2017. <i>Journal of Substance Abuse Treatment</i> , 2021, 126, 108484.	2.8	3
301	The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2068-2078.	0.4	16
302	Countyâ€“Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005â€“2017. <i>Hepatology</i> , 2021, 74, 582-590.	7.3	7
303	Injections and infections: understanding syringe service program utilization in a rural state. <i>Harm Reduction Journal</i> , 2021, 18, 74.	3.2	9
304	Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. <i>BMJ Open</i> , 2021, 11, e041490.	1.9	2
305	Machine learning takes a village: Assessing neighbourhood-level vulnerability for an overdose and infectious disease outbreak. <i>International Journal of Drug Policy</i> , 2021, 96, 103395.	3.3	13
306	Using Positive Empathy Interventions to Reduce Stigma Toward People Who Inject Drugs. <i>Frontiers in Psychology</i> , 2021, 12, 616729.	2.1	13

#	ARTICLE	IF	CITATIONS
307	Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab374.	0.9	4
308	Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2021, 94, 103198.	3.3	8
309	Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships. <i>Clinical Infectious Diseases</i> , 2022, 74, 993-1003.	5.8	3
310	Methodological approaches for the prediction of opioid use-related epidemics in the United States: a narrative review and cross-disciplinary call to action. <i>Translational Research</i> , 2021, 234, 88-113.	5.0	13
311	Food access among people who inject drugs in West Virginia. <i>Harm Reduction Journal</i> , 2021, 18, 90.	3.2	8
312	Risk factors for loss to follow-up of persons who inject drugs enrolled at syringe services programs in Kentucky. <i>International Journal of Drug Policy</i> , 2021, 95, 103255.	3.3	3
313	Healthcare stigma and HIV risk among rural people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108878.	3.2	20
314	Nursesâ€™ Descriptions of Interactions When Caring for Women With Perinatal Substance Use Disorders and Their Infants. <i>Nursing for Women's Health</i> , 2021, 25, 366-376.	0.8	3
315	Mouse Models for Studying HCV Vaccines and Therapeutic Antibodies. <i>Methods in Molecular Biology</i> , 2019, 1911, 481-503.	0.9	4
316	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. <i>Journal of Clinical Virology</i> , 2020, 124, 104285.	3.1	6
317	Negative affect, affect-related impulsivity, and receptive syringe sharing among people who inject drugs.. <i>Psychology of Addictive Behaviors</i> , 2020, 34, 734-744.	2.1	4
318	Substance use in rural Central Appalachia: Current status and treatment considerations.. <i>Journal of Rural Mental Health</i> , 2017, 41, 123-135.	0.9	101
319	Examining the Social Context of Injection Drug Use: Social Proximity to Persons Who Inject Drugs Versus Geographic Proximity to Persons Who Inject Drugs. <i>American Journal of Epidemiology</i> , 2017, 186, 970-978.	3.4	17
320	Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 71, 2986-2990.	5.8	7
321	Quantitative differences between intra-host HCV populations from persons with recently established and persistent infections. <i>Virus Evolution</i> , 2021, 7, veaa103.	4.9	9
322	Spatiotemporal Trends in Opioid Overdose Deaths by Race for Counties in Ohio. <i>Epidemiology</i> , 2021, 32, 295-302.	2.7	15
324	When is an abscess more than an abscess? Syringe services programs and the harm reduction safety-net: a case report. <i>Harm Reduction Journal</i> , 2020, 17, 34.	3.2	6
325	Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. <i>PLoS ONE</i> , 2017, 12, e0177341.	2.5	45

#	ARTICLE	IF	CITATIONS
326	Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas â€” United States, 2013. Morbidity and Mortality Weekly Report, 2015, 64, 1337-1341.	15.1	184
327	Increases in Acute Hepatitis B Virus Infections â€” Kentucky, Tennessee, and West Virginia, 2006â€“2013. Morbidity and Mortality Weekly Report, 2016, 65, 47-50.	15.1	107
328	Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission â€” United States and Kentucky, 2011â€“2014. Morbidity and Mortality Weekly Report, 2016, 65, 705-710.	15.1	113
329	Vital Signs: Trends in HIV Diagnoses, Risk Behaviors, and Prevention Among Persons Who Inject Drugs â€” United States. Morbidity and Mortality Weekly Report, 2016, 65, 1336-1342.	15.1	85
330	State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs â€” United States, 2015â€“2016. Morbidity and Mortality Weekly Report, 2017, 66, 465-469.	15.1	76
331	Hepatitis C Virus Infection Among Women Giving Birth â€” Tennessee and United States, 2009â€“2014. Morbidity and Mortality Weekly Report, 2017, 66, 470-473.	15.1	96
332	<i>Notes from the Field</i>: HIV Infection Investigation in a Rural Area â€” West Virginia, 2017. Morbidity and Mortality Weekly Report, 2018, 67, 257-258.	15.1	59
333	Invasive Methicillin-Resistant<i>Staphylococcus aureus</i> Infections Among Persons Who Inject Drugs â€” Six Sites, 2005â€“2016. Morbidity and Mortality Weekly Report, 2018, 67, 625-628.	15.1	110
334	Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports, 2018, 67, 1-31.	61.1	500
335	CDC Recommendations for Hepatitis C Screening Among Adults â€” United States, 2020. MMWR Recommendations and Reports, 2020, 69, 1-17.	61.1	316
336	Understanding the sepsis mortality belt: time to buckle down!. Annals of Translational Medicine, 2016, 4, 319-319.	1.7	4
337	Web-Based Eligibility Quizzes to Verify Opioid Use and County Residence Among Rural Young Adults: Eligibility Screening Results from a Feasibility Study. JMIR Research Protocols, 2019, 8, e12984.	1.0	6
338	Using Web-Based Pin-Drop Maps to Capture Activity Spaces Among Young Adults Who Use Drugs in Rural Areas: Cross-Sectional Survey. JMIR Public Health and Surveillance, 2019, 5, e13593.	2.6	7
339	Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial. Journal of Medical Internet Research, 2020, 22, e19703.	4.3	5
340	Computerized Tailored Interventions to Enhance Prevention and Screening for Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Randomized Pilot Study. JMIR Research Protocols, 2016, 5, e15.	1.0	10
341	Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014. Eurosurveillance, 2018, 23, .	7.0	2
342	Demographics of Hepatitis C in Southwest Ohio (2010 to 2015). Hepatitis Monthly, 2016, 16, e37904.	0.2	6
343	Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus. ELife, 2019, 8, .	6.0	10

#	ARTICLE	IF	CITATIONS
344	Outcomes of real-world integrated HCV microelimination for people who inject drugs: an expansion of the punjab model. <i>EClinicalMedicine</i> , 2021, 41, 101148.	7.1	8
345	The Impact of the Drug Epidemic on the Incidence of Sepsis in West Virginia. <i>Cureus</i> , 2018, 10, e3521.	0.5	6
347	Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 4, 100088.	1.0	1
348	HCV communication within ego-centric networks of men and women who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109157.	3.2	4
349	Collateral Damage: A Narrative Review on Epidemics of Substance Use Disorders and Their Relationships to Sexually Transmitted Infections in the United States. <i>Sexually Transmitted Diseases</i> , 2021, 48, 466-473.	1.7	11
350	Consuming illicit opioids during a drug overdose epidemic: Illicit fentanyl, drug discernment, and the radical transformation of the illicit opioid market. <i>International Journal of Drug Policy</i> , 2022, 99, 103467.	3.3	30
351	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. <i>Journal of Infectious Diseases</i> , 2020, 222, S741-S744.	4.0	1
352	Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 719-25.	15.1	262
353	Insights in Public Health: Reframing Hepatitis C: Lessons in Successful Public Health Collaboration. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2017, 76, 346-349.	0.4	0
354	Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. <i>Gastroenterology and Hepatology</i> , 2018, 14, 687-705.	0.1	2
355	A Simplified Algorithm for the Management of Hepatitis C Infection. <i>Gastroenterology and Hepatology</i> , 2019, 15, 1-12.	0.1	14
356	Identification of People Infected With Hepatitis C Virus Who Have Never Been Diagnosed. <i>Gastroenterology and Hepatology</i> , 2019, 15, 669-671.	0.1	0
357	The Relationship Between Polysubstance Injection Drug Use, HIV Risk Behaviors, and Interest in Pre-Exposure Prophylaxis (PrEP) Among People Who Inject Drugs in Rural West Virginia. <i>Journal of Studies on Alcohol and Drugs</i> , 2020, 81, 740-749.	1.0	5
358	Drugs of Abuse and Their Impact on Viral Pathogenesis. <i>Viruses</i> , 2021, 13, 2387.	3.3	8
359	Plasma virome and the risk of blood-borne infection in persons with substance use disorder. <i>Nature Communications</i> , 2021, 12, 6909.	12.8	8
360	Optical Biosensors for Diagnostics of Infectious Viral Disease: A Recent Update. <i>Diagnostics</i> , 2021, 11, 2083.	2.6	29
361	Opioid Use Disorder. <i>Annals of Internal Medicine</i> , 2022, 175, ITC1-ITC16.	3.9	16
362	People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination. <i>PLoS ONE</i> , 2022, 17, e0248850.	2.5	9

#	ARTICLE	IF	CITATIONS
363	Hepatitis C Treatment Knowledge and Practice Among Family Medicine Physicians in Wisconsin During the Current Hepatitis C Epidemic. Wisconsin Medical Journal, 2021, 120, 106-113.	0.3	0
364	Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection. International Journal of Environmental Research and Public Health, 2022, 19, 4158.	2.6	1
365	Testing a digitally distributed method to recruit a network of community organizations to fight the consequences of the drug epidemic: A study in 13 American states. Journal of Community Psychology, 2022, 50, 3455-3469.	1.8	0
366	Opioid Use Disorder Diagnosis and Management. , 2022, 1, .		5
367	Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy. PLoS ONE, 2022, 17, e0265811.	2.5	0
368	Viral hepatitis: Past, present, and future. World Journal of Gastroenterology, 2022, 28, 1405-1429.	3.3	29
369	Genotype Distribution and Demographic Characteristics of Hepatitis C Virus NAT Yield Cases among US Blood Donors. Clinical Infectious Diseases, 2022, , .	5.8	1
371	Postpartum Follow-up Care for Pregnant Persons With Opioid Use Disorder and Hepatitis C Virus Infection. Obstetrics and Gynecology, 2022, 139, 916-918.	2.4	12
372	Egocentric network characteristics of people who inject drugs in the Chicago metro area and associations with hepatitis C virus and injection risk behavior. Harm Reduction Journal, 2022, 19, .	3.2	7